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Design: Prospective	 nested	 qualitative	 cohort	 study	 embedded	within	 a	 national,	
multi‐site	randomized	controlled	trial	of	a	diagnostic	test	for	preeclampsia:	Placental	



















K E Y W O R D S
diagnostic	test,	preeclampsia,	pregnancy,	qualitative,	randomized	controlled	trial,	research
2  |     HAYES‐RYAN Et Al.
1  | INTRODUC TION
A	randomized	controlled	trial	(RCT)	is	regarded	as	the	gold	standard	
when	 testing	efficacy	of	 any	new	drug,	 intervention	or	diagnostic	
test.1,2	The	use	of	drugs	such	as	thalidomide	and	diethylstilbestrol	
in	pregnant	women	has	had	long‐lasting	repercussions,	with	women	











evidence‐based	 care	 for	 pregnant	 women.	 Interventions	 such	 as	
cardiotocography	and	foetal	fibronectin	testing	were	integrated	into	
clinical	practice	prior	to	robust	evidence	of	their	benefit.9	Once	use	









in	 research	 in	order	 to	help	guide	scientific‐based	practice	 for	all	
societal	groups.17‐19	With	the	advent	of	perinatal	research	centres,	
each	year	more	trials	specific	 to	pregnant	women	are	developed,	
funded	 and	 conducted	 globally.20,21	 Literature	 is	 sparse	 in	 rela‐
tion	to	women's	willingness	to	take	part	 in	clinical	research	while	
pregnant.22‐24	In	addition,	lack	of	experience	in	including	pregnant	
women	 in	 trials	may	 lead	 to	 poor	 trial	 design	 and	 hence	 recruit‐
ment	difficulties.25‐27	It	is	well	documented	that	under‐recruitment	
is	often	an	issue	in	RCTS,	with	a	third	not	reaching	target	and	over	














in	 the	 seven	 largest	 maternity	 units	 in	 Ireland,	 from	 29th	 June	
2017	 until	 26th	 April	 2019.	 The	 trial	 aimed	 to	 examine	whether	
the	addition	of	point‐of‐care	Placental	Growth	Factor	(PlGF)	test‐
ing	 to	 routine	 clinical	 care	 improved	both	maternal	 and	neonatal	
outcomes	 for	 women	 with	 a	 pre‐term	 singleton	 pregnancy,	 and	
signs	 or	 symptoms	of	 preeclampsia	 or	 placental	 dysfunction.29	 If	
an	eligible	pregnant	woman	consented	to	participate,	she	was	ran‐






2.2 | Nested qualitative study design
Participants	at	a	single	study	site	were	given	the	opportunity	to	par‐




Qualitative	 research	 has	 been	 utilized	 for	 many	 years	 to	 provide	
insight	 into	problems,	help	develop	hypotheses	and	to	gain	an	un‐
derstanding	 of	 underlying	 reasons,	 opinions	 and	 motivations.34 
Interviews	rather	than	surveys	were	employed	as	they	facilitated	a	
relationship	of	trust	to	be	established	between	the	researcher	and	




Purposive	 sampling	 of	 women	 who	 had	 recently	 completed	 the	
PARROT	RCT	was	employed	to	ensure	each	arm	of	 the	trial	was	






to	the	maternity	hospital	 in‐person	 (n	=	16)	or	were	 interviewed	
by	 telephone	 (n	 =	 3)	 if	 in‐person	 attendance	 was	 not	 feasible.	






















viewed	were	Caucasian,	 age	 ranged	 from	24	 to	42	years,	 and	52%	
were	nulliparous	prior	to	their	recent	pregnancy.	Four	themes	were	
identified	as	follows:	(a)	Understanding	of	preeclampsia,	(b)	Motivators	
















washing	 them	 and	 all	 those	 little	 preparation	 stuff	
that	I	was	kind	of	looking	forward	to	
P8


















Before	 being	 pregnant	 I	 don’t	 think…	 maybe	 I	 had	






I	 definitely	 thought	 that	 you	 were	 overweight	 and	
unfit	and	like	you'd	brought	it	on	yourself	kind	of	thing	
P9

















3.2 | Motivators for participation in clinical research
Despite	 limited	previous	experience	with	participation	in	research,	
especially	medical	 research,	 the	women	had	 extensive	 knowledge	




I	 just	 think	 information	 is	 power	 and	 the	 numbers	


































The	 potential	 of	 participation	 facilitating	 an	 opportunity	
of	 an	 earlier	 diagnosis,	 or	 identification	 of	 a	 problem,	 also	 influ‐
enced	women's	decision	 to	enrol.	Women	 felt	 that	by	being	part	
of	 the	 study	 they	might	 know	 sooner	 than	 others	 if	 they	 devel‐

























know	when	 the	 researcher	 approached	me	 directly,	
it’s	 kind	 of	 my	 responsibility	 “do	 you	 want	 to	 take	
part?”	whereas	when	 it	 comes	 from	you	 know	your	
consultant	it’s	an	easier	step	to	take	then	
P5
3.3 | Barriers to decision making
The	 main	 deterrent	 to	 participation	 in	 clinical	 research	 identified	
by	 the	 group	was	 risk.	 The	 group	 reported	 being	 highly	 reluctant	
to	take	part	in	any	research	should	they	perceive	it	as	being	poten‐
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don't	 want	 the	 baby	 to	 be	 the	 guinea	 pig	 either…	
you're	like	well	can	some	people	in	some	other	coun‐
tries	sign	up	 first	and	see	what	 the	outcome	 is.	You	





interviewed	as	 important	 to	 consider.	Many	participants	 reported	
that	 if	they	had	recently	received	sensitive	or	distressing	 informa‐


















ing	 its	medical	 research	–that	 can	 be	 scary.	Maybe,	
say	its	more	for	women’s	health	
P4

















plete	 a	 five‐page	paper	Quality	 of	 Life	 questionnaire	 at	 the	 time	






The	 researcher	 …	 she	 was	 dropping	 the	 follow‐up	
questionnaire,	 so	 she	could	know	 if	 I	needed	 to	get	
on	to	somebody	
P13





























It	 was	 really	 personable,	 it	 actually	 wasn’t	 like	 we	
were	just	another	case	number.	If	anything	it	brought	
me	 on	 sense	 of…somethings	 going	 right.	 Like	 there	
was	never	anything	bad	 to	come	out	of	 the	 trial	 for	
me,	 like	 worst	 case	 scenario	 you	 got	 nothing,	 you	




I	suppose,	all	 I	was	thinking	of	was	 if	 it	will	help	me	
or	help	other	people	I	will.	But	to	be	honest	informa‐


















on	 like,	 you	 know.	 I	 don’t	 remember	 ever	 a	 doctor	











lampsia	 among	 the	 group	 and	women	wanted	 information	on	 this	
condition	to	be	clear,	concise	and	provided	by	a	reliable	source.	 In	
our	 study,	 those	 randomized	 to	 the	 intervention	 felt	 participation	
in	 the	 trial	 directly	 benefited	 their	 pregnancy,	with	 the	 additional	
test	providing	valuable	information	on	placental	functioning	and	the	
perception	of	increased	care	from	clinicians.	On	reviewing	the	litera‐
ture,	we	 identified	 limited	numbers	of	 previous	 studies	 examining	
women's	experience	of	participation	in	a	RCT	while	pregnant.30‐33,39 
These	 RCTs	 vary	 in	 terms	 of	 design	 and	methodology,	 frequently	
involved	administration	of	a	medicinal	product	or	a	placebo.	Given	
















governance	of	 research	 trials	must	 be	 closely	 regulated	 to	 ensure	
this	vulnerable	group	are	not	exploited.
Respondents	 in	 our	 study	 reported	 being	more	 likely	 to	 take	
part	in	the	trial	if	it	was	mentioned	to	them	by	their	treating	clinician	
or	 a	member	of	 the	medical	 team.	Endorsement	of	 the	 trial	 from	
medical	personnel	appears	to	validate	a	study	for	patients.	Similarly	
a	 lack	of	 interest	or	 support	 from	 local	 clinical	 staff	has	been	 re‐




This	 nested	 study	 identified	 that	 the	 main	 barrier	 preventing	
participation	of	 pregnant	women	 in	 clinical	 research	 is	 the	poten‐
tial	of	causing	harm	to	the	baby.	Others	have	also	found	pregnant	
women	 to	 be	 risk	 adverse,	 with	 apprehension	 and	 risk	 limitation	
being	 common	barriers	 prohibiting	 participation.26,32	Clinical	 trials	
require	sponsorship,	insurance	and	undergo	rigorous	review	by	na‐
tional	 ethical	 committees	prior	 to	 their	 commencement.	On‐going	
clinical	trials	are	vigilantly	monitored	by	stakeholders,	to	ensure	any	
trends	in	adverse	events	are	quickly	detected	and	can	be	acted	upon	
with	 possible	 cessation	of	 the	 trial	 if	 necessary.11,21,40	Changing	 a	
pregnant	woman's	perception	of	risk	is	key.	Education,	through	the	
information	and	explanation	provided	by	researchers,	is	paramount.	






findings	 were	 reported	 in	 the	 QUOTE	 study,33	 while	 in	 contrast	
the	RIPE	study	 32	 reported	equal	 involvement	of	both	 the	women	
and	her	partner	 in	 the	decision	to	 take	part	 in	an	RCT.	Both	RCTs	
involved	 taking	 a	medication	while	 pregnant;	 however,	 in	QUOTE	
women	had	preeclampsia	when	enrolled,	whereas	 in	RIPE	healthy	
pregnant	women	were	 recruited.	This	 finding	highlights	 trials	 that	
involve	taking	a	medication	while	pregnant,	especially	 if	 recruiting	
healthy	 pregnant	 volunteers,	 likely	 require	 a	 longer	 time	 interval	
from	first	approach	by	researchers	until	signing	consent,	to	facilitate	
shared	decision	making.




propriate	 and	 the	 language	used	was	understandable	 and	unam‐
biguous.	 In	 contrast,	 participants	 of	 both	 the	MAGPIE41	 and	 the	
ORACLE42	RCTs	reported	confusion	when	the	trial	was	initially	ex‐
plained	to	them.	They	did	not	fully	understand	that	randomization	
meant	 they	might	not	 receive	 the	 intervention	and	subsequently	
had	limited	knowledge	and	recall	about	the	trials.30,33	This	differ‐
ence	may	 be	 attributable	 to	 the	 clinical	 situation	 of	 the	women	
at	 the	 time	 of	 recruitment.	 For	 PARROT	 Ireland,	 eligible	women	
were	 approached	 in	 a	 variety	 of	 clinical	 settings,	 antenatal	 clin‐
ics,	wards,	assessment	units,	all	while	undergoing	routine	assess‐
ments.	Both	the	MAGPIE	and	ORACLE	trials	 recruited	women	 in	
Labour	Ward/High	Dependency	Ward,	 either	 in	 pre‐term	 labour	
or	close	to	indicated	emergency	delivery.	Given	the	complexity	of	
these	clinical	situations,	it	 is	plausible	that	women	may	feel	over‐
whelmed	 and	 unable	 to	 clearly	 assimilate	 information	 provided	
about	 a	 research	 study.	Designing	 future	 trials	with	 recruitment	
focused	in	non‐emergent	situations	may	provide	a	solution	to	this,	
and	 ensure	 patient	 vulnerability	 is	 not	 exploited.	 An	 alternative	
could	be	to	employ	the	use	of	a	delayed	consent	process	for	labour	
ward‐based	trials.43	This	approach	has	been	employed	in	trials	of	


















The	 women	 we	 interviewed	 are	 likely	 to	 be	 highly	 moti‐
vated	 and	 interested	 in	 research	 as	 they	 not	 only	 took	 part	 in	
the	trial	during	their	pregnancy,	but	also	agreed	to	participate	in	
the	qualitative	 study.	 Ideally,	we	would	 have	 interviewed	 those	
who	declined	to	take	part	in	the	trial	also,	as	this	would	have	bet‐
ter	 elicited	 the	 barriers	 to	 research	 participation	 in	 pregnancy.	
However,	as	per	Good	Clinical	Practice	(GCP)45	and	General	Data	
Protection	Regulations	 (GDPR)46	we	did	not	retain	any	 informa‐
tion	 on	 eligible	 women	 who	 were	 approached	 but	 declined	 to	
participate	 in	 the	 trial,	 thus	 contacting	 them	 for	 this	 study	was	
not	feasible.	Strengths	of	our	study	include	in‐person	interviews,	
facilitating	a	more	personal	relationship	between	the	researcher	
and	 participant	 as	 well	 as	 close	 proximity	 of	 interview	 to	 time	
of	participation,	which	greatly	aided	participants	recall.	Uniquely,	








ticipation.	 The	 potential	 for	 personal	 benefit,	 through	 increased	
surveillance	 or	 earlier	 detection	 of	medical	 conditions,	was	 also	 a	
commonly	reported	motivator.	Similar	to	our	nested	study,	the	sys‐










by	 the	 research	midwife	of	our	 study.	Her	 candour	and	non‐pres‐





to	participate.	 It	 identifies	 that	 the	context,	purpose	and	potential	
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